Medicines Company The
Medicines Company The Newswire

Medicines Company The Newswire

Comprehensive Real-Time News Feed for Medicines Company The.

Results 1 - 20 of 208 in Medicines Company The

  1. Medicines Company v. Hospira IncRead the original story w/Photo

    Thursday Jul 2 | FindLaw

    Before DYK, WALLACH, and HUGHES, Circuit Judges. Edgar Haug, Frommer Lawrence & Haug LLP, New York, NY, argued for plaintiff-appellant.

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Thursday | Business Wire

    Our Ref. MH4428 ISIN Code. XS0... )--Fitch Ratings has affirmed the 'BBB-' rating on the following bonds issued by the Lee's Summit Industrial Development Authority on behalf of John Knox Village : ... )--F6 Networks, a New Brunswick provider of dark fibre and network services, today announced the completion of its 500 km northern New Brunswick Route conn... )--Regulatory News: Alpha M.O.S , createur et co-organisateur de l'edition 2015 d'ISOEN --COMMONWEALTH BANK OF AUSTRALIA Issue of EUR 50,000,000 Floating Rate Covered Bonds due October 2019 Series 22 Tranche 1 MTN ISSUE NAME.

    Comment?

  3. Will Medicines & Co. (MDCO) Stock be Hurt by Court Patent Ruling?Read the original story w/Photo

    Thursday Jul 2 | TheStreet.com

    The pharmaceutical company announced that the U.S. District Court of Delaware ruled that the company's claims that its '727 and '343 patents covering Angiomax were valid but that those patents were not infringed by Hospira's ANDA products. Both companies appealed the ruling with Medicines Co.

    Comment?

  4. Federal Circuit Rules Against The Medicines Company in Angiomax (bivalirudin) Patent LitigationRead the original story

    Thursday Jul 2 | Business Wire

    7,582,727 and 7,598,343 are invalid. On March 31, 2014, the U.S. District Court of Delaware found that all of the asserted claims of the '727 patent and the '343 patent covering Angiomax were valid but not infringed by Hospira's ANDA products.

    Comment?

  5. The Medicines Company Gets Approval For Cangrelor, But Uncertainty RemainsRead the original story w/Photo

    Monday Jun 29 | Seeking Alpha

    It has been a mixed year for The Medicines Company . Last week, the company received FDA approval for Kengreal .

    Comment?

  6. Edge Therapeutics' Chief Executive Officer Brian Leuthner Receives...Read the original story

    Friday Jun 26 | Freshnews

    Edge Therapeutics, Inc. today announced that Brian A. Leuthner, the company's Chief Executive Officer, President, and Co-founder, has received the EY Entrepreneur Of The Year 2015 New Jersey Region Award in the "Pharmaceutical & Diagnostic Private Companies" category. He was selected by an independent judging panel comprising previous winners of the award, leading CEOs, private capital investors and other regional business leaders.

    Comment?

  7. The Cheapest Medical Device Stock I've Ever SeenRead the original story w/Photo

    Friday Jun 26 | Seeking Alpha

    One of the biggest problems in surgical centers, emergency medical response and on the battlefield is bleeding. Surgeons working in blood-filled areas like the liver can hardly see what they are doing without spending inordinate amounts of time controlling bleeding.

    Comment?

  8. Premarket Biotech Digest: Valent May Buy Zoetis, Medicines Co.'s...Read the original story w/Photo

    Friday Jun 26 | Seeking Alpha

    Medicine Co. gets approval for Kengreal, BMY begins 2 trials in lung cancer and leukemia, Glaukos jumps 70% post IPO.

    Comment?

  9. The Medicines Company Said to Weigh Strategic Options for European UnitRead the original story

    Thursday Jun 25 | BioSpace

    Medicines Co. is weighing options including a sale for its European business as the drug developer seeks to benefit from the boom in health-care deals, according to people familiar with the matter.

    Comment?

  10. ErgoMed Selected By Co-Development Partner AEterna Zentaris To...Read the original story

    Wednesday Jun 24 | BioSpace

    Miroslav Reljanovic, Chief Executive Officer of Ergomed said: "We are delighted that Aeterna Zentaris has selected us to manage their confirmatory study of Macrilena . We have a strong and deep working relationship the Aeterna Zentaris scientific staff and hold them in the highest regard.

    Comment?

  11. Tokai Pharmaceuticals Announces Initiation Of Phase 3 ARMOR3-SV Trial ...Read the original story

    Tuesday Jun 23 | BioSpace

    Tokai Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the initiation of ARMOR3-SV, Tokai's pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. Tokai also announced today that the components of the AR-V7 clinical trial assay have been finalized by its collaborator, Qiagen , and that global deployment of the assay is now underway.

    Comment?

  12. FDA Approves The Medicines Company's Blood Clot Drug KENGREALRead the original story

    Monday Jun 22 | BioSpace

    The Medicines Company Announces FDA Approval of KENGREAL as an Adjunct to Percutaneous Coronary Intervention for Reducing Thrombotic Events Novel intravenous antiplatelet agent adds to MDCO commercial offerings in the cardiac cath lab Field force in place and product ready for supply in July PARSIPPANY, N.J.-- -- The Medicines Company today announced the approval of KENGREALa by the U.S. Food and Drug Administration as an adjunctive therapy to percutaneous coronary intervention for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor . This Smart News Release features multimedia.

    Comment?

  13. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Monday Jun 22 | Business Wire

    Dr. Morrison was recently appointed Chief Executive ... )--Research and Markets has announced the addition of the "Dissolved Gas Analyzer Market - Global Industry An... )--Research and Markets has announced the addition of the "Bosch Sensortec BME280 - Reverse Costing Analysi... )--Research and Markets has announced the addition of the "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... )--Mouser Electronics congratulates the winners in Mouser's Empowering Innovation Space Challenge - the latest contest in Mouser's Empowering Innovation To... )--Fitch Ratings has published an exposure draft with respect to its criteria for rating U.S. Tobacco Settlement ABS.

    Comment?

  14. The Medicines Company Announces FDA Approval of KENGREALa ...Read the original story

    Monday Jun 22 | Freshnews

    KENGREAL is the first and only intravenous, reversible P2Y12 platelet inhibitor with an immediate onset of action for patients undergoing PCI that, in clinical trials, has been shown to reduce the risk of periprocedural thrombotic events, including myocardial infarction, stent thrombosis, and repeat coronary revascularization. "The approval of KENGREAL provides a new option for PCI," said Clive A. Meanwell, MD, PhD, Chairman and Chief Executive Officer, The Medicines Company.

    Comment?

  15. The Medicines Company Announces FDA Approval of KENGREAL as an...Read the original story

    Monday Jun 22 | Benzinga

    The Medicines Company today announced the approval of KENGREAL by the U.S. Food and Drug Administration as an adjunctive therapy to percutaneous coronary intervention for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor . This Smart News Release features multimedia.

    Comment?

  16. Achaogen: An Undervalued Antibiotics Pharma CompanyRead the original story w/Photo

    Tuesday Jun 16 | Seeking Alpha

    Given slow enrollment in initial Phase 3 study in carbapenem-resistant enterobacteria, AKAO share price has declined twofold since its IPO in early 2014. At $100 million market cap, the AKAO share price has minimal downside but offers significant upside over the next two years.

    Comment?

  17. Now Available For Antimicrobial Susceptibility Testing, ORBACTIV...Read the original story

    Thursday Jun 11 | Laboratory Network .com

    The new antimicrobial oritavancin represents one of the latest treatment options for skin infections and is now available on FDA-cleared microbroth dilution susceptibility plates, giving microbiology laboratories the means for susceptibility testing of fastidious and non-fastidious gram positive organisms that cause skin infections in adults. Recognized for offering one of the largest and most up-to-date selections of FDA-cleared antimicrobials for susceptibility testing, the Thermo Scientific Sensititre ID/AST System is now the first to offer oritavancin on IVD-labeled microbroth dilution susceptibility plates.

    Comment?

  18. The Medicines Company Product Pipeline Review 2015: Worldwide...Read the original story

    Friday Jun 12 | Emailwire.com

    ResearchMoz.us includes new market research report " The Medicines Company Product Pipeline Review 2015: Global Industry Analysis, Sahres, Size, Trends, Grwoth, and Forecast report" to its huge collection of research reports. This report provides comprehensive information on the current therapeutic developmental pipeline of The Medicines Companys, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type.

    Comment?

  19. Alnylam Slaps Dicerna With Lawsuit Over Trade SecretsRead the original story

    Wednesday Jun 10 | BioSpace

    By this lawsuit, Alnylam seeks to stop misappropriation by Dicerna of the company's confidential, proprietary, and trade secret information related to, among other things, GalNAc conjugate technology. "Alnylam has led the discovery and development of GalNAc conjugate technology for delivery of RNA therapeutics, including through technology we obtained from our $175 million Sirna Therapeutics acquisition in our 2014 transaction with Merck," said Barry Greene, President and Chief Operating Officer of Alnylam.

    Comment?

  20. Radius Health Plans to Double Staff in 2015, Exec Tells BioSpaceRead the original story w/Photo

    Wednesday Jun 10 | BioSpace

    June 11, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Waltham, Mass.-based Radius Health is focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.

    Comment?